United Therapeutics (NASDAQ:UTHR) Price Target Lowered to $355.00 at JPMorgan Chase & Co.

United Therapeutics (NASDAQ:UTHR) had its target price lowered by research analysts at JPMorgan Chase & Co. from $357.00 to $355.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 25.24% from the company’s current price.

UTHR has been the topic of several other reports. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Bank of America raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price on the stock in a research report on Monday. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $395.67.

United Therapeutics Trading Down 0.4 %

Shares of UTHR traded down $1.28 during midday trading on Monday, reaching $283.45. The stock had a trading volume of 120,200 shares, compared to its average volume of 451,048. The firm has a 50 day simple moving average of $316.61 and a 200-day simple moving average of $348.62. The firm has a market cap of $12.73 billion, a PE ratio of 12.45, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics has a one year low of $233.28 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period last year, the firm posted $4.36 earnings per share. As a group, research analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at $10,437,712.18. The trade was a 23.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $370.71, for a total value of $3,707,100.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $955,319.67. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 91,500 shares of company stock worth $30,971,540 over the last three months. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC raised its position in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 30 shares during the last quarter. Parallel Advisors LLC grew its holdings in United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 30 shares during the period. Anchor Investment Management LLC raised its position in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 30 shares in the last quarter. Great Lakes Advisors LLC lifted its stake in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after purchasing an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after purchasing an additional 33 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.